Telo Genomics Corp Net Income
| TDSGF Stock | USD 0.04 0.01 15.62% |
As of the 14th of February 2026, Telo Genomics has the Risk Adjusted Performance of 0.0274, coefficient of variation of 4405.98, and Semi Deviation of 7.15. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Telo Genomics Corp, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Telo Genomics Corp, which can be compared to its competition. Please validate Telo Genomics Corp treynor ratio, as well as the relationship between the downside variance and kurtosis to decide if Telo Genomics is priced more or less accurately, providing market reflects its prevalent price of 0.037 per share. As Telo Genomics Corp appears to be a penny stock we also recommend to double-check its total risk alpha numbers.
Telo Genomics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Telo Genomics' valuation are provided below:Telo Genomics Corp does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Telo |
Telo Genomics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Telo Genomics' otc stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Telo Genomics.
| 11/16/2025 |
| 02/14/2026 |
If you would invest 0.00 in Telo Genomics on November 16, 2025 and sell it all today you would earn a total of 0.00 from holding Telo Genomics Corp or generate 0.0% return on investment in Telo Genomics over 90 days. Telo Genomics is related to or competes with Interpace Biosciences, and Healthlynked Corp. Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological pro... More
Telo Genomics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Telo Genomics' otc stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Telo Genomics Corp upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 18.27 | |||
| Information Ratio | 0.0146 | |||
| Maximum Drawdown | 48.57 | |||
| Value At Risk | (15.00) | |||
| Potential Upside | 15.63 |
Telo Genomics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telo Genomics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Telo Genomics' standard deviation. In reality, there are many statistical measures that can use Telo Genomics historical prices to predict the future Telo Genomics' volatility.| Risk Adjusted Performance | 0.0274 | |||
| Jensen Alpha | 0.1159 | |||
| Total Risk Alpha | (0.45) | |||
| Sortino Ratio | 0.0069 | |||
| Treynor Ratio | 0.1596 |
Telo Genomics February 14, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0274 | |||
| Market Risk Adjusted Performance | 0.1696 | |||
| Mean Deviation | 4.51 | |||
| Semi Deviation | 7.15 | |||
| Downside Deviation | 18.27 | |||
| Coefficient Of Variation | 4405.98 | |||
| Standard Deviation | 8.62 | |||
| Variance | 74.24 | |||
| Information Ratio | 0.0146 | |||
| Jensen Alpha | 0.1159 | |||
| Total Risk Alpha | (0.45) | |||
| Sortino Ratio | 0.0069 | |||
| Treynor Ratio | 0.1596 | |||
| Maximum Drawdown | 48.57 | |||
| Value At Risk | (15.00) | |||
| Potential Upside | 15.63 | |||
| Downside Variance | 333.83 | |||
| Semi Variance | 51.16 | |||
| Expected Short fall | (11.65) | |||
| Skewness | (0.71) | |||
| Kurtosis | 3.15 |
Telo Genomics Corp Backtested Returns
Telo Genomics Corp owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0223, which indicates the firm had a -0.0223 % return per unit of risk over the last 3 months. Telo Genomics Corp exposes twenty-seven different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Telo Genomics' Risk Adjusted Performance of 0.0274, semi deviation of 7.15, and Coefficient Of Variation of 4405.98 to confirm the risk estimate we provide. The entity has a beta of 1.16, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Telo Genomics will likely underperform. At this point, Telo Genomics Corp has a negative expected return of -0.19%. Please make sure to validate Telo Genomics' treynor ratio and the relationship between the downside variance and day typical price , to decide if Telo Genomics Corp performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.00 |
No correlation between past and present
Telo Genomics Corp has no correlation between past and present. Overlapping area represents the amount of predictability between Telo Genomics time series from 16th of November 2025 to 31st of December 2025 and 31st of December 2025 to 14th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Telo Genomics Corp price movement. The serial correlation of 0.0 indicates that just 0.0% of current Telo Genomics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | -0.2 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Telo Genomics Corp reported net income of (2.11 Million). This is 100.62% lower than that of the Health Care Technology sector and 101.22% lower than that of the Health Care industry. The net income for all United States stocks is 100.37% higher than that of the company.
Telo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.Telo Genomics is currently under evaluation in net income category among its peers.
Telo Fundamentals
| Return On Equity | -0.78 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 13.73 M | |||
| Shares Outstanding | 59.42 M | |||
| Shares Owned By Insiders | 6.52 % | |||
| Shares Owned By Institutions | 1.83 % | |||
| Price To Earning | (0.67) X | |||
| Price To Book | 10.46 X | |||
| EBITDA | (2.05 M) | |||
| Net Income | (2.11 M) | |||
| Cash And Equivalents | 2.69 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 40 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 14.66 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (1.79 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 16 | |||
| Beta | 1.87 | |||
| Market Capitalization | 12.81 M | |||
| Total Asset | 2.83 M | |||
| Net Asset | 2.83 M |
About Telo Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Telo OTC Stock
Telo Genomics financial ratios help investors to determine whether Telo OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Telo with respect to the benefits of owning Telo Genomics security.